Pridopidine, an investigational therapy developed for Huntington's disease, recently faced a significant hurdle when the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommended against its approval. This decision poses a challenge as it influences the European
Emerging as a groundbreaking innovation in biomedical sciences, Organ-on-Chips (OoC) technology has begun to transform traditional approaches to drug research and development. At the forefront of this revolution, these microengineered devices offer a physiological simulation of human organs,
In the ever-evolving landscape of biotechnology and pharmaceuticals, Ivan Kairatov stands as a respected authority, particularly in tech and innovation within the biopharma sector. He joins us today to discuss recent developments concerning a compound known as inidascamine. Originally developed by
Emerging at the intersection of biotechnology and artificial intelligence, Absci is positioning itself as a transformative entity in the drug discovery landscape. This strategic positioning comes as the company recently announced a significant $50 million capital raise, a maneuver that underscores
Johnson & Johnson (J&J) is making significant strides in immunology drug development by embracing a pathway-centric approach to redefining autoimmune disease treatment under the leadership of Dr. Katie Abouzahr. This strategy diverges from traditional methods by prioritizing a multi-indication
The landscape of drug discovery, particularly for complex neurodegenerative diseases like ALS (Amyotrophic Lateral Sclerosis), is undergoing rapid transformation with the advent of artificial intelligence. Louisiana is making significant strides in this arena with the inception of the Louisiana AI
